Staff News Editor at Diabetes Week -- Novo Nordisk A/S (Bagsvaerd, DK) has been issued patent number 8614181, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors.
The patent's inventors are Juul-Mortensen, Claus (Kobenhavn V, DK); Engelund, Dorte Kot (Holte, DK).
This patent was filed on November 5, 2009 and was published online on December 24, 2013.
From the background information supplied by the inventors, news correspondents obtained the following quote: "Therapeutic peptides are widely used in medical practise. Pharmaceutical compositions of such therapeutic peptides are required to have a shelf life of several years in order to be suitable for common use. However, peptide compositions are inherently unstable due to sensitivity towards chemical and physical degradation. Chemical degradation involves change of covalent bonds, such as oxidation, hydrolysis, racemization or crosslinking. Physical degradation involves conformational changes relative to the native structure of the peptide, i.e. secondary and tertiary structure, such as aggregation, precipitation or adsorption to surfaces.
Read the full article on 4Traders.com